glutathione mold and Mycotoxin Illness: Its Connection to ME/CFS, MCAS, and Chronic Symptoms Glutathione for Mold Detox: Evidence

Noor N, Urits I, Degueure A, et al

The data were expressed as arithmetic mean standard deviation (SD) and minimum/medium/maximum

Gaddy JA, Tomaras AP, Actis LA

Records: Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction

Third, the evidence hierarchy matters when justifying compound selection in research documentation

In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday